Compliance with national guidelines for the management of drug-drug interactions in dutch community pharmacies

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 2024-2031

  Buurma, Henk ^a,b   Schalekamp, Tom ^b   Egberts, Antoine C G ^b,c   De Smet, Peter A G M ^d,e  

^a SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c GGZ Midden Brabant   (Netherlands)

^d Scientific Institute Dutch Pharmacists   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Compliance; Drug related problem; Drug drug interaction; Guideline; Intervention; Pharmaceutical care; Pharmacist; Risk management

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; COUMARIN DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIGOXIN; ERYTHROMYCIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MACROLIDE; METHOTREXATE; NITRATE; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PRAVASTATIN; QUINOLONE DERIVATIVE; SILDENAFIL; SIMVASTATIN; SULFONAMIDE; TERBINAFINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; UNINDEXED DRUG; VARDENAFIL;

ARTICLE; BLEEDING; BONE MARROW SCINTISCANNING; BONE MARROW SUPPRESSION; CONFIDENCE INTERVAL; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERACTION; DRUG SUBSTITUTION; DRUG TOXICITY; DRUG WITHDRAWAL; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; MYOPATHY; NETHERLANDS; PATIENT CARE; PHARMACY; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; RHABDOMYOLYSIS; RISK FACTOR; SEX RATIO; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMMUNITY PHARMACY SERVICES; DRUG INTERACTIONS; FEMALE; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PHARMACISTS;

EID: 36849052281     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K240     Document Type: Article

References (19)

1. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003;362:1225-30.
2. Sandars J, Esmail A. The frequency and nature of medical error in primary care: understanding the diversity across studies. Fam Pract 2003;20:231-6.
3. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human. Building a safer health system. Washington, DC: National Academy Press, 1999.
4. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother 1999;33:1336-55. DOI 10.1345/aph.18440
5. Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol 2004;58:503-11.
6. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993;9:51-9.
7. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003;26:983-9.
8. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug- drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
9. Van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005;28:1131-9.
10. Commentaren Medicatiebewaking 2004-2005 [Commentaries medication surveillance]. Houten, Netherlands: Health Base, 2004.
11. Opstelten W, van Essen GA, Moons KG, et al. Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Fam Pract 2005;22:523-8.
12. Van Duijn HJ, Kuyvenhoven MM, Schellevis FG, Verheij TJ. Determinants of prescribing of second-choice antibiotics for upper and lower respiratory tract episodes in Dutch general practice. J Antimicrob Chemother 2005;56:420-2.
13. Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br J Gen Pract 2003;53:600-6.
14. Muijrers PE, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RP. Changing relationships: attitudes and opinions of general practitioners and pharmacists regarding the role of the community pharmacist. Pharm World Sci 2003;25:235-41.
15. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003;163:2625-31.
16. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001;69:260-5.
17. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-70.
18. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240-7.
19. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in the Netherlands. Pharm World Sci 1999;21:217-20.